Protein Drugs-EMEA Market Status and Trend Report 2013-2023
Report Summary
Protein Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Protein Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Protein Drugs 2013-2017, and development forecast 2018-2023
Main market players of Protein Drugs in EMEA, with company and product introduction, position in the Protein Drugs market
Market status and development trend of Protein Drugs by types and applications
Cost and profit status of Protein Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA Protein Drugs market as:
EMEA Protein Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Protein Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Antibody Drugs
Peptide Hormones
Blood Products
Enzymes
EMEA Protein Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
AIDS
Cancer
Hepatitis
Diabetes
Others
EMEA Protein Drugs Market: Players Segment Analysis (Company and Product introduction, Protein Drugs Sales Volume, Revenue, Price and Gross Margin):
Eli Lilly
Abbott Laboratories
UCB Group
Schering-Plough Corporation
Genentech
Johnson＆Johnson
Bristol-Myers Squibb
Novo Nordisk
Biogen Idec
Dendreon Corporation
Amgen
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Protein Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Protein Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Protein Drugs 2013-2017, and development forecast 2018-2023
Main market players of Protein Drugs in EMEA, with company and product introduction, position in the Protein Drugs market
Market status and development trend of Protein Drugs by types and applications
Cost and profit status of Protein Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA Protein Drugs market as:
EMEA Protein Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Protein Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Antibody Drugs
Peptide Hormones
Blood Products
Enzymes
EMEA Protein Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
AIDS
Cancer
Hepatitis
Diabetes
Others
EMEA Protein Drugs Market: Players Segment Analysis (Company and Product introduction, Protein Drugs Sales Volume, Revenue, Price and Gross Margin):
Eli Lilly
Abbott Laboratories
UCB Group
Schering-Plough Corporation
Genentech
Johnson＆Johnson
Bristol-Myers Squibb
Novo Nordisk
Biogen Idec
Dendreon Corporation
Amgen
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF PROTEIN DRUGS
1.1 Definition of Protein Drugs in This Report
1.2 Commercial Types of Protein Drugs
1.2.1 Antibody Drugs
1.2.2 Peptide Hormones
1.2.3 Blood Products
1.2.4 Enzymes
1.3 Downstream Application of Protein Drugs
1.3.1 AIDS
1.3.2 Cancer
1.3.3 Hepatitis
1.3.4 Diabetes
1.3.5 Others
1.4 Development History of Protein Drugs
1.5 Market Status and Trend of Protein Drugs 2013-2023
1.5.1 EMEA Protein Drugs Market Status and Trend 2013-2023
1.5.2 Regional Protein Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Protein Drugs in EMEA 2013-2017
2.2 Consumption Market of Protein Drugs in EMEA by Regions
2.2.1 Consumption Volume of Protein Drugs in EMEA by Regions
2.2.2 Revenue of Protein Drugs in EMEA by Regions
2.3 Market Analysis of Protein Drugs in EMEA by Regions
2.3.1 Market Analysis of Protein Drugs in Europe 2013-2017
2.3.2 Market Analysis of Protein Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Protein Drugs in Africa 2013-2017
2.4 Market Development Forecast of Protein Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Protein Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Protein Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Protein Drugs in EMEA by Types
3.1.2 Revenue of Protein Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Protein Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Protein Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Protein Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Protein Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Protein Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Protein Drugs by Downstream Industry in Africa
4.3 Market Forecast of Protein Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PROTEIN DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Protein Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 PROTEIN DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Protein Drugs in EMEA by Major Players
6.2 Revenue of Protein Drugs in EMEA by Major Players
6.3 Basic Information of Protein Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Protein Drugs Major Players
6.3.2 Employees and Revenue Level of Protein Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PROTEIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Eli Lilly
7.1.1 Company profile
7.1.2 Representative Protein Drugs Product
7.1.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
7.2 Abbott Laboratories
7.2.1 Company profile
7.2.2 Representative Protein Drugs Product
7.2.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.3 UCB Group
7.3.1 Company profile
7.3.2 Representative Protein Drugs Product
7.3.3 Protein Drugs Sales, Revenue, Price and Gross Margin of UCB Group
7.4 Schering-Plough Corporation
7.4.1 Company profile
7.4.2 Representative Protein Drugs Product
7.4.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Schering-Plough Corporation
7.5 Genentech
7.5.1 Company profile
7.5.2 Representative Protein Drugs Product
7.5.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Genentech
7.6 Johnson＆Johnson
7.6.1 Company profile
7.6.2 Representative Protein Drugs Product
7.6.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson＆Johnson
7.7 Bristol-Myers Squibb
7.7.1 Company profile
7.7.2 Representative Protein Drugs Product
7.7.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.8 Novo Nordisk
7.8.1 Company profile
7.8.2 Representative Protein Drugs Product
7.8.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.9 Biogen Idec
7.9.1 Company profile
7.9.2 Representative Protein Drugs Product
7.9.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Biogen Idec
7.10 Dendreon Corporation
7.10.1 Company profile
7.10.2 Representative Protein Drugs Product
7.10.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
7.11 Amgen
7.11.1 Company profile
7.11.2 Representative Protein Drugs Product
7.11.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROTEIN DRUGS
8.1 Industry Chain of Protein Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PROTEIN DRUGS
9.1 Cost Structure Analysis of Protein Drugs
9.2 Raw Materials Cost Analysis of Protein Drugs
9.3 Labor Cost Analysis of Protein Drugs
9.4 Manufacturing Expenses Analysis of Protein Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF PROTEIN DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Protein Drugs in This Report
1.2 Commercial Types of Protein Drugs
1.2.1 Antibody Drugs
1.2.2 Peptide Hormones
1.2.3 Blood Products
1.2.4 Enzymes
1.3 Downstream Application of Protein Drugs
1.3.1 AIDS
1.3.2 Cancer
1.3.3 Hepatitis
1.3.4 Diabetes
1.3.5 Others
1.4 Development History of Protein Drugs
1.5 Market Status and Trend of Protein Drugs 2013-2023
1.5.1 EMEA Protein Drugs Market Status and Trend 2013-2023
1.5.2 Regional Protein Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Protein Drugs in EMEA 2013-2017
2.2 Consumption Market of Protein Drugs in EMEA by Regions
2.2.1 Consumption Volume of Protein Drugs in EMEA by Regions
2.2.2 Revenue of Protein Drugs in EMEA by Regions
2.3 Market Analysis of Protein Drugs in EMEA by Regions
2.3.1 Market Analysis of Protein Drugs in Europe 2013-2017
2.3.2 Market Analysis of Protein Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Protein Drugs in Africa 2013-2017
2.4 Market Development Forecast of Protein Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Protein Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Protein Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Protein Drugs in EMEA by Types
3.1.2 Revenue of Protein Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Protein Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Protein Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Protein Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Protein Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Protein Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Protein Drugs by Downstream Industry in Africa
4.3 Market Forecast of Protein Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PROTEIN DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Protein Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 PROTEIN DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Protein Drugs in EMEA by Major Players
6.2 Revenue of Protein Drugs in EMEA by Major Players
6.3 Basic Information of Protein Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Protein Drugs Major Players
6.3.2 Employees and Revenue Level of Protein Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PROTEIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Eli Lilly
7.1.1 Company profile
7.1.2 Representative Protein Drugs Product
7.1.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
7.2 Abbott Laboratories
7.2.1 Company profile
7.2.2 Representative Protein Drugs Product
7.2.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.3 UCB Group
7.3.1 Company profile
7.3.2 Representative Protein Drugs Product
7.3.3 Protein Drugs Sales, Revenue, Price and Gross Margin of UCB Group
7.4 Schering-Plough Corporation
7.4.1 Company profile
7.4.2 Representative Protein Drugs Product
7.4.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Schering-Plough Corporation
7.5 Genentech
7.5.1 Company profile
7.5.2 Representative Protein Drugs Product
7.5.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Genentech
7.6 Johnson＆Johnson
7.6.1 Company profile
7.6.2 Representative Protein Drugs Product
7.6.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson＆Johnson
7.7 Bristol-Myers Squibb
7.7.1 Company profile
7.7.2 Representative Protein Drugs Product
7.7.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.8 Novo Nordisk
7.8.1 Company profile
7.8.2 Representative Protein Drugs Product
7.8.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.9 Biogen Idec
7.9.1 Company profile
7.9.2 Representative Protein Drugs Product
7.9.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Biogen Idec
7.10 Dendreon Corporation
7.10.1 Company profile
7.10.2 Representative Protein Drugs Product
7.10.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
7.11 Amgen
7.11.1 Company profile
7.11.2 Representative Protein Drugs Product
7.11.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROTEIN DRUGS
8.1 Industry Chain of Protein Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PROTEIN DRUGS
9.1 Cost Structure Analysis of Protein Drugs
9.2 Raw Materials Cost Analysis of Protein Drugs
9.3 Labor Cost Analysis of Protein Drugs
9.4 Manufacturing Expenses Analysis of Protein Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF PROTEIN DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
